A Phase 2 interventional study of Buspirone and Placebo in Cannabis Use Disorder, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-06-02.
Sponsored by The University of Texas Health Science Center, Houston · Phase 2, Interventional, and Basic science
This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone.
Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.
For nearly 40 years marijuana has remained the most widely used illicit drug in the US, with more than 50% of first-time users \< age 18. Marijuana accounts for ≈ 60% of illicit substance use disorders (SUD) in the US, bearing by percent the largest US public health burden among illicit substances. Across preclinical, human laboratory, and clinical interview data, there is compelling evidence that the phenomenon of cue reactivity is related to drug seeking and relapse. Attentional bias is a measurable component of cue reactivity, and can be operationally defined as differential attention (e.g., reaction time difference) towards drug-related stimuli vs. neutral stimuli. This phenomenon has been demonstrated in SUD populations across many classes of abused drugs, including alcohol, nicotine, stimulants, opiates, and - importantly - marijuana. Cue reactivity and attentional bias are exacerbated by acute and chronic stress and anxiety. Notably, stress is a well-documented predictor of marijuana abuse and marijuana relapse. Therapeutic interventions that attenuate attentional bias to marijuana cues are a potentially important component in the treatment of marijuana SUD. Due to the well-documented association with stress, an intervention that simultaneously addresses both stress and attentional bias could be uniquely efficacious. Currently, few pharmacotherapies exist for marijuana SUD, and none are presently known to address attentional bias to marijuana cues. This application will explore the potential of the anxiolytic buspirone to modify attentional bias and stress. Buspirone is a unique compound marked by modulation of both serotonin (5-HT1A) and dopamine D3 receptors. Importantly, the 5-HT1A receptor is known to play a key role in stress related anxiety, and preclinical work indicates that D3 antagonists significantly decrease cue reactivity to a number of abused drugs. This combination of effects suggests buspirone may be advantageous in targeting both stress and attentional bias as factors that contribute to problem marijuana use.
Accordingly, this project seeks to examine the effects of chronic buspirone administration on attentional bias and stress/anxiety in marijuana SUD. Using laboratory-based methodologies sensitive to attentional bias towards marijuana cues and well validated measures of stress and anxiety, we will examine if buspirone's unique mechanism of action will (a) produce an attenuation of attentional bias to marijuana cues, and (b) be most pronounced under conditions in which attentional bias is related to high levels of stress and anxiety.
517 studies on the registry are indexed under Marijuana Abuse; 114 are open to participants now.
This study's enrollment of 45 is below the median of 60 across 421 interventional studies indexed under Marijuana Abuse.
Browse Marijuana Abuse studies →The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Drug: Buspirone
Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Drug: Placebo
Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Also known as: corn starch
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time frame: week 1
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time frame: week 2
Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time frame: week 3
Stress as Assessed by the Perceived Stress Scale
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time frame: week 1
Stress as Assessed by the Perceived Stress Scale
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time frame: week 2
Stress as Assessed by the Perceived Stress Scale
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time frame: week 3
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Time frame: week 1
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Time frame: week 2
Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
Time frame: week 3
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time frame: week 1
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time frame: week 2
Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time frame: week 3
| Milestone | Buspirone | Placebo |
|---|---|---|
| Started | 19 | 23 |
| Completed | 16 | 16 |
| Not completed | 3 | 7 |
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
| ratio of errors (see OM description) | Buspirone | Placebo |
|---|---|---|
| Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements | 0.5795019 ± 0.1609511 | 0.5539831 ± 0.1442601 |
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
| ratio of errors (see OM description) | Buspirone | Placebo |
|---|---|---|
| Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements | 0.5517691 ± 0.1319968 | 0.4979594 ± 0.1486691 |
Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: \[(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)\]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
| ratio of errors (see OM description) | Buspirone | Placebo |
|---|---|---|
| Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements | 0.5503957 ± 0.1133407 | 0.531073 ± 0.1991689 |
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Perceived Stress Scale | 15.05556 ± 5.885898 | 18.57895 ± 6.551639 |
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Perceived Stress Scale | 13.88889 ± 6.434182 | 16.42105 ± 5.708822 |
The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Perceived Stress Scale | 10.38889 ± 6.436467 | 14.05263 ± 7.799385 |
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Anxiety as Assessed by the Zung Self-Rated Anxiety Scale | 32.44444 ± 2.955 | 32.52632 ± 4.880442 |
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Anxiety as Assessed by the Zung Self-Rated Anxiety Scale | 31.5 ± 3.714043 | 31.57895 ± 3.79057 |
The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: * 20-44 Normal Range * 45-59 Mild to Moderate Anxiety Levels * 60-74 Marked to Severe Anxiety Levels * 75-80 Extreme Anxiety Levels
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Anxiety as Assessed by the Zung Self-Rated Anxiety Scale | 33.27778 ± 4.884616 | 31.63158 ± 4.125941 |
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) | 3.888889 ± 2.373602 | 3.631579 ± 3.515213 |
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) | 3 ± 2.44949 | 2.789474 ± 2.636895 |
With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
| units on a scale | Buspirone | Placebo |
|---|---|---|
| Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) | 1.944444 ± 1.862074 | 2.526316 ± 2.50263 |
Collected over 3 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Buspirone | — | 0/19 (0%) | 1/19 (5.3%) |
| Placebo | — | 0/23 (0%) | 0/23 (0%) |
| Event | Buspirone | Placebo |
|---|---|---|
| light-headed, dizzinessNervous system disorders | 1/19 | 0/23 |
| Age, Continuous(years) | Buspirone | Placebo | Total |
|---|---|---|---|
| Mean | 29.16 ± 7.15 | 29.52 ± 6.89 | 29.34 ± 7.02 |
| Sex: Female, Male(Participants) | Buspirone | Placebo | Total |
|---|---|---|---|
| Female | 8 | 10 | 18 |
| Male | 11 | 13 | 24 |
| Region of Enrollment(participants) | Buspirone | Placebo | Total |
|---|---|---|---|
| United States | 19 | 23 | 42 |
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of Texas Health Science Center, Houston